Takeda Taps Ultragenyx To Step Up Rare Disease Efforts
This article was originally published in PharmAsia News
In its second deal in recent days, Takeda is moving more decisively into the rare disease space through a licensing and collaborative R&D alliance with the specialist US firm Ultragenyx.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.